Quantcast

Latest Glycogen storage disease type II Stories

2010-01-11 07:00:00

CRANBURY, N.J., Jan. 11 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today outlined the Company's three key strategic priorities and presented a corporate outlook for 2010 at the 28th Annual J.P. Morgan Healthcare Conference. "In 2010 our strategic priorities are clear and we remain steadfast in executing our business goals. We are committed to focusing our resources on three value-creating centers within Amicus. Advancing our global Amigal Phase 3 program is our...

2009-10-14 07:30:00

MILWAUKEE, Oct. 14 /PRNewswire/ -- ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of...

2009-09-30 07:00:00

CRANBURY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced it plans to initiate a Phase 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in development for the treatment of Pompe Disease. The primary objective of this study is to evaluate the pharmacokinetics of AT2220 in muscle tissue in healthy adult subjects. The U.S. Food and Drug Administration (FDA) has agreed to Amicus' proposal for the Phase 1 study and...

2009-05-26 07:24:43

Brain may win out over brawn as the primary cause of breathing problems in children with a severe form of muscular dystrophy known as Pompe disease.Researchers at the Powell Gene Therapy Center at the University of Florida have discovered that signals from the brain to the diaphragm "” the muscle that controls breathing "” are too weak to initiate healthy respiration in mouse models of the disease.The discovery for the first time shifts responsibility to the nervous system for the...

2009-02-27 08:30:00

CRANBURY, N.J., Feb. 27 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that the Company has suspended enrollment for the Phase 2 clinical trial of its investigational drug AT2220 (1-deoxynojirimycin HCI) for the treatment of Pompe Disease and that it has received verbal notice from the U.S. Food and Drug Administration (FDA) that the trial is on clinical hold. After evaluation of available data the Company plans to work closely with the FDA and if appropriate...

2009-02-18 15:00:00

CRANBURY, N.J., Feb. 18 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that Stephen Bloch, M.D., General Partner with Canaan Equity Partners, has resigned from the Company's Board of Directors effective February 17, 2009. Dr. Bloch served as a member of Amicus' board since 2004. About Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of...

2009-01-29 07:00:00

CRANBURY, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce fourth quarter and full year 2008 financial results after the regular close of markets on Thursday, February 5, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EST. Interested participants and investors may access the conference call at 5 p.m. EST by dialing 877-675-4756 (U.S./Canada) or 719-325-4870 (international). A telephonic...

2009-01-12 14:00:00

Company Expects to Deliver Multiple Clinical Milestones throughout the Year; Amigal to Initiate Phase 3 Global Development in Second Quarter; Continued Strong Financial Position CRANBURY, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced positive progress in its three lead clinical programs for lysosomal storage disorders and presented a corporate outlook consisting of multiple clinical milestones and financial guidance for 2009 at the 27th Annual...

2009-01-08 12:15:00

The life of a Minnesota boy suffering with a rare and serious form of the genetic disorder Pompe disease has been extended after treatment with a drug typically used to suppress the immune system of those with cancer and rheumatoid arthritis.Rituxan, or rituximab,  is a monoclonal antibody made by Genentech Inc and Biogen Idec.  It consists of genetically engineered immune system molecules, and is used to treat non-Hodgkin's lymphoma, rheumatoid arthritis and other conditions.Dr....

2009-01-08 07:00:00

CRANBURY, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election of Sol J. Barer, Ph.D., to its Board of Directors. Dr. Barer currently serves as Chairman and Chief Executive Officer of Celgene Corporation. As an industry veteran, Dr. Barer brings over 20 years of management experience and a reputation as a trusted and respected leader who has helped transform Celgene into one of the world's preeminent biopharmaceutical companies. John F....


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related